These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18083698)

  • 1. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents.
    Pusztai L
    Ann Oncol; 2007 Dec; 18 Suppl 12():xii15-20. PubMed ID: 18083698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes.
    Yardley DA
    Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
    Dumontet C; Jordan MA; Lee FF
    Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxanes, microtubules and chemoresistant breast cancer.
    McGrogan BT; Gilmartin B; Carney DN; McCann A
    Biochim Biophys Acta; 2008 Apr; 1785(2):96-132. PubMed ID: 18068131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
    Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
    BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
    Lopus M; Smiyun G; Miller H; Oroudjev E; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1013-24. PubMed ID: 26416565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms.
    Vahdat L
    Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ixabepilone: a new microtubule-targeting agent for breast cancer.
    Higa GM; Abraham J
    Expert Rev Anticancer Ther; 2008 May; 8(5):671-81. PubMed ID: 18471040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
    Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies to overcome taxane resistance in cancer.
    Das T; Anand U; Pandey SK; Ashby CR; Assaraf YG; Chen ZS; Dey A
    Drug Resist Updat; 2021 Mar; 55():100754. PubMed ID: 33691261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.
    Horak CE; Pusztai L; Xing G; Trifan OC; Saura C; Tseng LM; Chan S; Welcher R; Liu D
    Clin Cancer Res; 2013 Mar; 19(6):1587-95. PubMed ID: 23340299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current perspectives of epothilones in breast cancer.
    Cardoso F; de Azambuja E; Lago LD
    Eur J Cancer; 2008 Feb; 44(3):341-52. PubMed ID: 18178426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubulin interacting agents: novel taxanes and epothilones.
    Agrawal NR; Ganapathi R; Mekhail T
    Curr Oncol Rep; 2003 Mar; 5(2):89-98. PubMed ID: 12583825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixabepilone for the treatment of taxane-refractory breast cancer.
    Moulder SL
    Future Oncol; 2008 Jun; 4(3):333-40. PubMed ID: 18518758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
    Hari M; Loganzo F; Annable T; Tan X; Musto S; Morilla DB; Nettles JH; Snyder JP; Greenberger LM
    Mol Cancer Ther; 2006 Feb; 5(2):270-8. PubMed ID: 16505100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
    Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
    Brogdon CF; Lee FY; Canetta RM
    Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
    Wang W; Zhang H; Wang X; Patterson J; Winter P; Graham K; Ghosh S; Lee JC; Katsetos CD; Mackey JR; Tuszynski JA; Wong GK; Ludueña RF
    Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.